GP 1644

Rev. 04/01

Docket No. A061CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Gregory R. Mundy and Toshiyuki Yoneda
Application No.:		10/086,217
Confirmation No.:		5114
Filed	:	February 21, 2002
For	:	METHODS OF TREATING MULTIPLE MYELOMA AND MYELOMA-INDUCED BONE RESORPTION USING INTEGRIN ANTAGONISTS
Group Art Unit	:	1644
Examiner	:	Not yet assigned

New York, New York
July 1, 2002

Hon. Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement, PTO-1449 Form (in duplicate) and documents cited therein. This Statement is submitted:

[ ] within three months of the application filing date;

[X] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge

payment of any fees required in connection with this Supplemental Information Disclosure Statement to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Stanley D. Liang (Reg. No. 43,753)
Agent for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

I Hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to:
COMMISSIONER FOR PATENTS P.O. Box 2327
ARLINGTON, VA 22202 on

July 1, 2002
Lillian Garcia

Lillian Garcia
Signature of Person Signing

#41

A061CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Gregory R. Mundy and Toshiyuki Yoneda
Application No.	:	10/086,217
Confirmation No.	:	5114
Examiner	:	Not yet assigned
Group Art Unit	:	1644
Filed	:	February 21, 2002
For	:	METHODS OF TREATING MULTIPLE MYELOMA AND MYELOMA-INDUCED BONE RESORPTION USING INTEGRIN ANTAGONISTS

New York, New York
July 1, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants, through their attorney and agent, make of record the following documents in the above-identified patent application, copies of which are submitted herewith:

UNITED STATES PATENTS

5,510,332 (Kogan et al.) issued April 23, 1996

FOREIGN PATENT APPLICATIONS AND PUBLICATIONS

PCT publication WO 99/61421	Published December 2, 1999
PCT publication WO 00/15247	Published March 23, 2000
PCT publication WO 01/12186	Published February 22, 2001

OTHER REFERENCES

Masellis-Smith et al. "Adhesion of Multiple Myeloma Peripheral B Cells to Bone Marrow Fibroblasts: A Requirement for CD44 and $\alpha_4\beta_7$", Cancer Research 57(5): 930-936 (1997).

Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Database Medline 'Online!: US National Library of Medicine (NLM), Bethesda, MD, US, retrieved from STN, Database accession no. 1998026745, abstract.

Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Cancer 80 (8 Suppl): 1557-1563 (1997, Oct. 15).

Akatsu et al. "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro", Database BIOSIS 'Online!: Biosciences Information Service, Philadelphia, PA, US (August 1998) Database accession no. PREV199800429141, abstract.

Akatsu et al. "Chinese Hamster Ovary Cells Expressing $\alpha_4\beta_1$ Integrin Stimulate Osteoclast Formation In Vitro", Journal of Bone and Mineral Research 13 (8): 1251-1259 (1998).

Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta1 Integrin – VCAM-1 is required for the Development of Osteolysis", Database SCISEARCH 'Online!, retrieved from STN, Database accession no. 684996.

Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via $\alpha_4\beta_1$ Integrin–VCAM-1 is required for the Development of Osteolysis", Journal of Bone and Mineral Research 12 Supp. 1, p. S128, Abstract 104 (1997).

Mori et al. "Anti-α4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions", Journal of Bone and Mineral Research 14 Supp. 1, p. S173, Abstract 1161 (1999).

REMARKS

The above-cited documents, with the exception of two (WO 00/15247 and WO 01/12186), were cited in the International Search Report of PCT application number PCT/US99/21170, a great-grandparent application of the above-identified application.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next official communication.

Applicants request favorable action in this application.



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Stanley D. Liang (Reg. No. 43,753)
Agent for Applicants
c/o FISH & NEAVE (Customer No. 1473)
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax.: (212) 596-9090

I Hereby Certify that this Correspondence is being Deposited with the U.S. Postal Service as First Class Mail in an Envelope Addressed to: COMMISSIONER FOR PATENTS P.O. Box 2327 ARLINGTON, VA 22202 on

July 1, 2002

Lillian Garcia

Lillian Garcia

Signature of Person Signing

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	FILING DATE February 21, 2002	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,510,332	4/23/96	Kogan et al.	514	14	July 7, 1994

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	WO 99/61421	12/2/99	PCT	C07D	207/16		
	WO 00/15247	3/23/00	PCT	A61K	38/17		
	WO 01/12186	2/22/01	PCT	A61K	31/40		

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	FILING DATE February 21, 2002	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Masellis-Smith et al. "Adhesion of Multiple Myeloma Peripheral B Cells to Bone Marrow Fibroblasts: A Requirement for CD44 and $\alpha_4\beta_7$", Cancer Research 57(5): 930-936 (1997).
	Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Database Medline 'Online!: US National Library of Medicine (NLM), Bethesda, MD, US, retrieved from STN, Database accession no. 1998026745, abstract.
	Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Cancer 80 (8 Suppl): 1557-1563 (1997, Oct. 15).
	Akatsu et al."Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro", Database BIOSIS 'Online!: Biosciences Information Service, Philadelphia, PA, US, (August 1998) Database accession no. PREV199800429141, abstract.
	Akatsu et al."Chinese Hamster Ovary Cells Expressing $\alpha_4\beta_1$ Integrin Stimulate Osteoclast Formation In Vitro", Journal of Bone and Mineral Research 13 (8): 1251-1259 (1998).
	Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta1 Integrin - VCAM-1 is required for the Development of Osteolysis", Database SCISEARCH 'Online!, retrieved from STN, Database accession no. 684996.
	Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via $\alpha_4\beta_1$ Integrin - VCAM-1 is required for the Development of Osteolysis", Journal of Bone and Mineral Research 12 Supp. 1, p.S128, Abstract 104 (1997).
	Mori et al. "Anti-α4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions", Journal of Bone and Mineral Research 14 Supp. 1, p. S173, Abstract 1161 (1999).

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.